You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

recombinant SARS-CoV-2 vaccine

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

COVID-19 Trial in Shang Qiu (low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell), high-dose Recombinant SARS-CoV-2 Vaccine (CHO

Active, not recruiting
  • COVID-19
  • low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)
  • +2 more
  • Shang Qiu, He Nan, China
    Ning ling Center for Disease Control and Prevention
Jan 31, 2023

COVID-19, Vaccine Reaction Trial in Chengdu (LYB001, CoronaVac)

Active, not recruiting
  • COVID-19
  • Vaccine Reaction
  • LYB001
  • CoronaVac
  • Chengdu, Sichuan, China
    Chengdu Xinhua Hospital Affiliated to North Sichuan Medical Coll
Jun 29, 2023

SARS-CoV-2 Trial in Nanjing (SARS-CoV-2 Bivalent mRNA Vaccine, Recombinant SARS-CoV-2 vaccine, Saline)

Not yet recruiting
  • SARS-CoV-2
  • SARS-CoV-2 Bivalent mRNA Vaccine
  • +2 more
  • Nanjing, Jiangsu, China
    Jiangsu Provincial Center for Disease Control and Prevention
Jul 7, 2023

COVID-19 Trial in Wuhan (Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001, ZF2001)

Active, not recruiting
  • COVID-19
  • Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001
  • ZF2001
  • Wuhan, Hubei, China
    Hubei Provincial Center for Disease Control and Prevention
Jan 12, 2023

COVID-19 Trial in Chengdu (LYB002V14, LYB002V14A, LYB002CA)

Active, not recruiting
  • COVID-19
  • LYB002V14
  • +2 more
  • Chengdu, Sichuan, China
    Affiliated Hospital of North Sichuan MedicalCollege
Jun 29, 2023

Covid-19 Vaccine Trial (PIKA COVID-19 vaccine)

Not yet recruiting
  • Covid-19 Vaccine
  • PIKA COVID-19 vaccine
  • (no location specified)
Jul 17, 2022

COVID-19 Trial in Nanjing (Recombinant SARS-CoV-2 Ad5 vectored vaccine, Inactive SARS-CoV-2 vaccine (Vero cell))

Completed
  • COVID-19
  • Recombinant SARS-CoV-2 Ad5 vectored vaccine
  • Inactive SARS-CoV-2 vaccine (Vero cell)
  • Nanjing, Jiangsu, China
    Jiangsu Provincial Center for Disease Control and Prevention
Mar 28, 2022

COVID-19 Trial in Chongqing, Jinan (Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001, Placebo)

Active, not recruiting
  • COVID-19
  • Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001
  • Placebo
  • Chongqing, Chongqing, China
  • +1 more
Jan 11, 2023

COVID-19 Trial in Guangzhou (the recombinant SARS-CoV-2 S-Trimer vaccine/inactivated SARS-CoV-2 vaccine)

Recruiting
  • COVID-19
  • the recombinant SARS-CoV-2 S-Trimer vaccine/inactivated SARS-CoV-2 vaccine
  • Guangzhou, Guangzhou, China
    The Fifth Affiliated Hospital of Guangzhou Medical University
Jan 28, 2023

COVID-19 Trial in Nanjing (low-dose LYB001, Recombinant COVID-19 Vaccine (CHO Cell), high-dose LYB001)

Active, not recruiting
  • COVID-19
  • low-dose LYB001
  • +2 more
  • Nanjing, Jiangsu, China
    Jiangsu Provincial Center for Disease Control and Prevention
Dec 25, 2022

COVID-19 Trial in Nanjing (Two doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14,

Recruiting
  • COVID-19
  • Two doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14
  • +7 more
  • Nanjing, Jiangsu, China
    Jiangsu Provincial Center for Diseases Control and Prevention
Mar 28, 2022

COVID-19 Trial in Kunming (ZR-202-CoV, Placebo)

Recruiting
  • COVID-19
  • ZR-202-CoV
  • Placebo
  • Kunming, Yunan, China
    Clinical Trial Institution for Anning First Hospital
Apr 5, 2022

COVID-19 Vaccine Trial in Ciudad Autónoma de Buenos Aires (ARVAC-CG vaccine (recombinant protein vaccine against SARS-CoV-2))

Active, not recruiting
  • COVID-19 Vaccine
  • ARVAC-CG vaccine (recombinant protein vaccine against SARS-CoV-2)
  • Ciudad Autónoma de Buenos Aires, Argentina
    Unidad de Investigación Clínica Farmacocinética FP Clinical Phar
Dec 21, 2022

COVID-19 Trial in Nanjing (One dose group, Two doses group, Aged 18-59 years)

Not yet recruiting
  • COVID-19
  • One dose group
  • +3 more
  • Nanjing, Jiangsu, China
    Jiangsu Provincial Center for Disease Control and Prevention
Dec 25, 2022

SARS-CoV-2 Vaccine in Metabolism-related Fatty Liver Disease

Not yet recruiting
  • Metabolic Associated Fatty Liver Disease
  • Recombinant protein vaccine and adenovirus vector vaccine
  • (no location specified)
Feb 12, 2023

Covid19 Trial in Jakarta (SARS-CoV-2 Protein Subunit Recombinant Vaccine, SARS-CoV-2 Inactivated Vaccine)

Completed
  • Covid19
  • SARS-CoV-2 Protein Subunit Recombinant Vaccine
  • SARS-CoV-2 Inactivated Vaccine
  • Jakarta, Greater Jakarta, Indonesia
    Fakultas Kedokteran Universitas Indonesia
Aug 8, 2022

COVID-19 Trial (LYB001, Placebo)

Not yet recruiting
  • COVID-19
  • LYB001
  • Placebo
  • (no location specified)
Oct 26, 2022

COVID-19 Vaccine Trial in Argentina (Gamma Variant RBD-based ARVAC-CG vaccine, Omicron Variant RBD-based ARVAC-CG vaccine,

Recruiting
  • COVID-19 Vaccine
  • Gamma Variant RBD-based ARVAC-CG vaccine
  • +3 more
  • Argentina, C.a.b.a., Argentina
    Centro de Educación Médica e Investigaciones Clínicas "Norberto
Feb 28, 2023

SARS-CoV-2 Infection Trial in Mexico City (Recombinant NDV Vectored Vaccine for SARS-CoV-2)

Completed
  • SARS-CoV-2 Infection
  • Recombinant NDV Vectored Vaccine for SARS-CoV-2
  • Mexico City, Ciudad De Mexico, Mexico
    Hospital Medica Sur
Dec 8, 2022

COVID-19 Trial in Semarang, Jakarta (SARS-CoV-2 protein subunit recombinant vaccine, SARS-CoV-2 inactivated vaccine)

Active, not recruiting
  • COVID-19
  • SARS-CoV-2 protein subunit recombinant vaccine
  • SARS-CoV-2 inactivated vaccine
  • Semarang, Central Java, Indonesia
  • +1 more
Aug 8, 2022

SARS-CoV-2 Infection Trial in Baltimore (B/HPIV3/S-6P)

Recruiting
  • SARS-CoV-2 Infection
  • B/HPIV3/S-6P
  • Baltimore, Maryland
    Johns Hopkins Bloomberg School of Public Health
Aug 30, 2023

COVID-19 Trial in Changsha (Recombinant Novel Coronavirus vaccine (CHO Cells))

Completed
  • COVID-19
  • Recombinant Novel Coronavirus vaccine (CHO Cells)
  • Changsha, Hunan, China
    Hunan Provincial Center for Disease Control and Prevention
Jun 6, 2023

COVID-19 Trial (SARS-CoV-2 Subunit Recombinant Protein Vaccine)

Not yet recruiting
  • COVID-19
  • SARS-CoV-2 Subunit Recombinant Protein Vaccine
  • (no location specified)
Jul 5, 2023

COVID-19 Trial in Manila, Putatan (SCB-2023 vaccine (trivalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for

Not yet recruiting
  • COVID-19
  • SCB-2023 vaccine (trivalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection
  • SCB-2019 (monovalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection
  • Manila, Philippines
  • +2 more
Jun 21, 2023

Covid19 Trial in Tehran (SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant, Saline )

Completed
  • Covid19
  • SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant
  • Saline placebo
  • Tehran, Iran, Islamic Republic of
    Espinas Palace Hotel
Oct 11, 2022